Total Payments
$547,313
2024 Payments
$128,884
Companies
32
Transactions
931
Medicare Patients
64,437
Medicare Billing
$5.6M
Payment Breakdown by Category
Other$457,988 (83.7%)
Travel$42,956 (7.8%)
Consulting$25,699 (4.7%)
Food & Beverage$20,191 (3.7%)
Education$479.64 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $457,988 | 173 | 83.7% |
| Travel and Lodging | $42,956 | 173 | 7.8% |
| Consulting Fee | $25,699 | 11 | 4.7% |
| Food and Beverage | $20,191 | 565 | 3.7% |
| Education | $479.64 | 9 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $165,156 | 300 | $0 (2024) |
| Lilly USA, LLC | $110,343 | 142 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $75,145 | 111 | $0 (2024) |
| PFIZER INC. | $66,962 | 90 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $51,999 | 59 | $0 (2024) |
| GENZYME CORPORATION | $28,057 | 24 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $24,255 | 48 | $0 (2023) |
| Dermavant Sciences, Inc. | $22,406 | 22 | $0 (2024) |
| Janssen Biotech, Inc. | $480.19 | 26 | $0 (2021) |
| LEO Pharma Inc. | $469.28 | 28 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $128,884 | 163 | Lilly USA, LLC ($49,413) |
| 2023 | $114,910 | 171 | Lilly USA, LLC ($60,580) |
| 2022 | $35,424 | 67 | ABBVIE INC. ($23,863) |
| 2021 | $21,317 | 35 | Novartis Pharmaceuticals Corporation ($9,899) |
| 2020 | $23,366 | 47 | Novartis Pharmaceuticals Corporation ($9,531) |
| 2019 | $88,756 | 154 | AbbVie, Inc. ($36,964) |
| 2018 | $83,080 | 158 | AbbVie, Inc. ($30,298) |
| 2017 | $51,576 | 136 | AbbVie, Inc. ($30,581) |
All Payment Transactions
931 individual payment records from CMS Open Payments — Page 1 of 38
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/10/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,880.00 | General |
| Category: Immunology | ||||||
| 12/10/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Travel and Lodging | Cash or cash equivalent | $150.08 | General |
| Category: Immunology | ||||||
| 12/05/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $1,218.20 | General |
| 12/05/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $600.00 | General |
| 12/03/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $19.53 | General |
| Category: IMMUNOLOGY | ||||||
| 11/26/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Education | In-kind items and services | $85.47 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/25/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $3.25 | General |
| Category: IMMUNOLOGY | ||||||
| 11/12/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $124.52 | General |
| Category: Immunology | ||||||
| 10/31/2024 | Lilly USA, LLC | OLUMIANT (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,250.00 | General |
| Category: Immunology | ||||||
| 10/30/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $18.70 | General |
| Category: IMMUNOLOGY | ||||||
| 10/16/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $20.22 | General |
| Category: IMMUNOLOGY | ||||||
| 10/11/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $29.34 | General |
| Category: IMMUNOLOGY | ||||||
| 10/09/2024 | ABBVIE INC. | RINVOQ (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,025.00 | General |
| Category: IMMUNOLOGY | ||||||
| 10/09/2024 | Hill Dermaceuticals, Inc. | Tolak (Drug) | Food and Beverage | Cash or cash equivalent | $9.68 | General |
| Category: Topical | ||||||
| 09/30/2024 | Lilly USA, LLC | OLUMIANT (Drug) | Travel and Lodging | Cash or cash equivalent | $255.94 | General |
| Category: Immunology | ||||||
| 09/24/2024 | Lilly USA, LLC | OLUMIANT (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,500.00 | General |
| Category: Immunology | ||||||
| 09/24/2024 | Lilly USA, LLC | OLUMIANT (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,200.00 | General |
| Category: Immunology | ||||||
| 09/20/2024 | Lilly USA, LLC | OLUMIANT (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,500.00 | General |
| Category: Immunology | ||||||
| 09/20/2024 | Lilly USA, LLC | OLUMIANT (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,200.00 | General |
| Category: Immunology | ||||||
| 09/19/2024 | Lilly USA, LLC | OLUMIANT (Drug) | Food and Beverage | Cash or cash equivalent | $103.88 | General |
| Category: Immunology | ||||||
| 09/18/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $2,701.21 | General |
| 09/18/2024 | Lilly USA, LLC | OLUMIANT (Drug) | Food and Beverage | Cash or cash equivalent | $124.97 | General |
| Category: Immunology | ||||||
| 09/17/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $3.41 | General |
| Category: IMMUNOLOGY | ||||||
| 09/12/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $65.05 | General |
| Category: IMMUNOLOGY | ||||||
| 09/09/2024 | Lilly USA, LLC | OLUMIANT (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,250.00 | General |
| Category: Immunology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 53 | 17,358 | 32,061 | $4.2M | $1.5M |
| 2022 | 55 | 15,759 | 28,775 | $3.7M | $1.4M |
| 2021 | 53 | 15,976 | 29,693 | $3.7M | $1.4M |
| 2020 | 48 | 15,344 | 27,475 | $3.7M | $1.2M |
Total Patients
64,437
Total Services
118,004
Medicare Billing
$5.6M
Procedure Codes
209
All Medicare Procedures & Services
209 procedure records from CMS Medicare Utilization — Page 1 of 9
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 3,945 | 5,948 | $688,481 | $364,683 | 53.0% |
| 17311 | Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, 1-5 tissue blocks | Office | 2023 | 271 | 324 | $340,738 | $150,224 | 44.1% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 2,549 | 3,478 | $369,398 | $134,355 | 36.4% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 1,452 | 1,747 | $521,899 | $110,120 | 21.1% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 1,100 | 1,313 | $231,246 | $101,511 | 43.9% |
| 88305 | Pathology examination of tissue using a microscope, intermediate complexity | Office | 2023 | 1,555 | 2,924 | $513,189 | $72,622 | 14.2% |
| 12032 | Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | Office | 2023 | 288 | 311 | $149,815 | $68,919 | 46.0% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 1,874 | 10,861 | $134,133 | $51,718 | 38.6% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 641 | 641 | $109,693 | $47,217 | 43.0% |
| 17004 | Destruction of precancer skin growth, 15 or more growths | Office | 2023 | 309 | 391 | $112,848 | $45,931 | 40.7% |
| J7308 | Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) | Office | 2023 | 78 | 120 | $77,908 | $34,299 | 44.0% |
| 17312 | Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, each additional stage, 1-5 tissue blocks | Office | 2023 | 83 | 101 | $62,428 | $33,144 | 53.1% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 669 | 775 | $53,328 | $30,421 | 57.0% |
| 11602 | Removal of cancer skin growth of body, arms, or legs, 1.1-2.0 cm | Office | 2023 | 200 | 234 | $92,297 | $24,941 | 27.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 230 | 276 | $47,091 | $23,640 | 50.2% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2023 | 360 | 579 | $93,294 | $21,349 | 22.9% |
| 12034 | Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 7.6-12.5 cm | Office | 2023 | 63 | 69 | $34,169 | $17,454 | 51.1% |
| 15260 | Full thickness skin graft to nose, ears, eyelids, or lips, 20.0 sq cm or less | Office | 2023 | 21 | 21 | $33,969 | $16,446 | 48.4% |
| 12052 | Intermediate repair of wound of face, ears, eyelids, nose, lips, or mouth, 2.6-5.0 cm | Office | 2023 | 91 | 92 | $43,053 | $14,263 | 33.1% |
| 12042 | Intermediate repair of wound of neck, hands, feet, or genitals, 2.6-7.5 cm | Office | 2023 | 56 | 58 | $26,653 | $14,070 | 52.8% |
| 17262 | Destruction of cancer skin growth of trunk, arms, or legs, 1.1-2.0 cm | Office | 2023 | 97 | 108 | $23,895 | $12,408 | 51.9% |
| 96573 | Application of light by qualified health care professional to destroy precancer skin growth | Office | 2023 | 52 | 64 | $16,483 | $11,612 | 70.5% |
| 14061 | Repair of wound of eyelids, nose, ears, or lips by transferring skin, 10.1-30.0 sq cm | Office | 2023 | 15 | 15 | $24,290 | $10,920 | 45.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 90 | 90 | $23,549 | $10,842 | 46.0% |
| 11622 | Removal of cancer skin growth of scalp, neck, hands, feet, or genitals, 1.1-2.0 cm | Office | 2023 | 81 | 84 | $34,256 | $10,590 | 30.9% |
About Dr. Daniel Hurd, DO
Dr. Daniel Hurd, DO is a Dermatology healthcare provider based in Blacksburg, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/29/2005. The National Provider Identifier (NPI) number assigned to this provider is 1841290897.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Daniel Hurd, DO has received a total of $547,313 in payments from pharmaceutical and medical device companies, with $128,884 received in 2024. These payments were reported across 931 transactions from 32 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($457,988).
As a Medicare-enrolled provider, Hurd has provided services to 64,437 Medicare beneficiaries, totaling 118,004 services with total Medicare billing of $5.6M. Data is available for 4 years (2020–2023), covering 209 distinct procedure/service records.
Ad
Practice Information
- Specialty Dermatology
- Location Blacksburg, VA
- Active Since 07/29/2005
- Last Updated 08/26/2010
- Taxonomy Code 207N00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1841290897
Products in Payments
- OLUMIANT (Drug) $90,516
- DUPIXENT (Biological) $68,775
- EUCRISA (Drug) $65,497
- Humira (Biological) $55,843
- Sotyktu (Drug) $50,081
- SKYRIZI (Biological) $34,192
- RINVOQ (Biological) $25,847
- COSENTYX (Biological) $24,186
- Skyrizi (Biological) $23,478
- VTAMA (Drug) $22,406
- DUPIXENT (Drug) $20,032
- DUPIXENT DUPILUMAB INJECTION (Biological) $14,653
- HUMIRA (Biological) $7,231
- ENSTILAR (Drug) $377.93
- TALTZ (Drug) $349.47
- Otezla (Drug) $225.16
- OPZELURA (Drug) $201.12
- Erivedge (Biological) $182.36
- CIBINQO (Drug) $125.37
- Tremfya (Drug) $123.65
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.